Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio, Inc.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Atlas Venture

New Enterprise Associates

Alexandria Venture Investments

Wu Capital

MP Healthcare Venture Management

Surveyor Capital

Cormorant Asset Management

Qiming Venture Partners USA

Monashee Investment Management

Invus

Verition Fund Management

Fidelity

Point72

Sixty Degree Capital

Fidelity Management and Research Company

We’re pleased to announce that Korro Bio will be attending the TD Cowen 44th Annual Health Care Conference in Boston.

Our Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Monday, March 4, 2024, at 2:10 PM ET.

Tune in for a live webcast of the presentation at: https://ir.korrobio.com/

https://lnkd.in/eT4CnDQr

#KorroBio #TDCowen #TDCowenHealthCare Cowen Inc.

#ICYMI, the Korro team attended the Nasdaq Closing Bell Ringing Ceremony on Tuesday. Thank you to Nasdaq for hosting us and your collaboration. Our team had an incredibly humbling moment celebrating our success.

Here's to Korro’s ongoing innovation as we advance #RNAediting.

Missed the livestream? Catch the recording here: https://lnkd.in/eZkjHPRS 

#KorroBio #ClosingBell

We are pleased to announce the key highlights from our presentation at the J.P. Morgan Healthcare Conference last week. We shared data for our lead program in Alpha-1 Antitrypsin Deficiency (AATD) and our pipeline.  

To read more about our recent accomplishments, see the full press release: bit.ly/3HncrAX

To view our corporate presentation, go to: https://bit.ly/3vEWOCx 

#JPM2024 #JPMorganHealthcare #KorroBio

We invite you to tune in to the live webcast today at 11:15 am PT / 2:15 pm ET. Our CEO and President, Ram Aiyar, will share the corporate update at the J.P. Morgan Healthcare Conference. Learn more about our progress in expanding the frontiers of genetic medicines through #RNAediting.

To view the presentation, visit: bit.ly/41VtvHN

To listen to the webcast, go to: https://lnkd.in/g4n4jJqk

Vineet Agarwal Steve Colletti

#JPMorganHealthcare #JPM2024 #KorroBio

	Dec '21	Dec '22	Dec '23
account payables	789K -	2.60M 230.16%	7.28M 179.46%
accumulated other comprehensive income loss	-7K -	-5K 28.57%
cash and cash equivalents	83.49M -	36.33M 56.48%	166.15M 357.30%
cash and short term investments	118.53M -	55.25M 53.39%	166.15M 200.73%
common stock	5K -		8K -
deferred revenue	-2.58M -	2.97M 215.04%	9.37M 215.70%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory	-144K -
long term debt	14.17M -	209K 98.52%	31.22M 14,835.89%
long term investments	13.42M -	4.54M 66.16%	3.41M 24.99%
net debt	-37.89M -	-33.20M 12.38%	-132.94M 300.39%
net receivables	144K -
other assets
other current assets	1.24M -	1.23M 0.88%	3.02M 144.72%
other current liabilities	4.16M -	207K 95.02%	842K 306.76%
other liabilities
other non current assets	-12.76M -	228K 101.79%	2.71M 1,090.35%
other non current liabilities	150.67M -	163.86M 8.76%	1.05M 99.36%
othertotal stockholders equity	1.59M -	2.81M 75.99%	352.91M 12,472.43%
preferred stock
property plant equipment net	7.14M -	11.89M 66.50%	42.81M 260.09%
retained earnings	-43.80M -	-101.83M 132.49%	-183.00M 79.71%
short term debt	2.58M -	2.92M 13.22%	1.99M 31.84%
short term investments	35.04M -	18.91M 46.02%
tax assets
tax payables
total assets	127.58M -	73.74M 42.20%	221.66M 200.59%
total current assets	119.78M -	57.08M 52.34%	172.73M 202.59%
total current liabilities	4.95M -	8.70M 75.81%	19.48M 123.92%
total debt	45.60M -	3.13M 93.14%	33.21M 960.93%
total investments	35.04M -	18.91M 46.02%	3.41M 81.99%
total liabilities	169.78M -	172.77M 1.76%	51.75M 70.05%
total liabilities and stockholders equity	127.58M -	73.74M 42.20%	221.66M 200.59%
total non current assets	7.80M -	16.66M 113.58%	48.94M 193.75%
total non current liabilities	164.83M -	164.07M 0.46%	32.27M 80.33%
total stockholders equity	-42.21M -	-99.03M 134.63%	169.91M 271.57%

KRRO

COM:KORROBIO

Korro Bio

Last Close

50.62

22/11 21:00

Market Cap

385.94M

Beta: -

Volume Today

67.40K

Avg: -

Preview